Cargando…

SARS-CoV-2/Omicron subvariants: global outbreak upsurge and expected upcoming threats

Detalles Bibliográficos
Autores principales:	Malik, Sumira, Uniyal, Priyanka, Bora, Jutishna, Haque, Shafiul, Swed, Sarya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389191/ https://www.ncbi.nlm.nih.gov/pubmed/36799814 http://dx.doi.org/10.1097/JS9.0000000000000240

Ejemplares similares

An update on current understanding of the epidemiology and management of the re-emerging endemic Lassa fever outbreaks
por: Malik, Sumira, et al.
Publicado: (2023)

Ebola virus disease (EVD) outbreak re-emergence regulation in East Africa: preparedness and vaccination perspective
por: Malik, Sumira, et al.
Publicado: (2023)

Antibiotic resistance in agriculture: Perspectives on upcoming strategies to overcome upsurge in resistance
por: Mann, Avantika, et al.
Publicado: (2021)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

Genomic evidence for reinfection with different Omicron subvariants
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C. Paul, et al.
Publicado: (2022)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

The First Outbreak of Omicron Subvariant BA.5.2 — Beijing Municipality, China, July 4, 2022
por: Feng, Zhaomin, et al.
Publicado: (2022)

Women in ophthalmology – An upsurge!
por: Bansal, Rolika, et al.
Publicado: (2022)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Modelling the impact of the Omicron BA.5 subvariant in New Zealand
por: Lustig, Audrey, et al.
Publicado: (2023)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
por: Li, Yaning, et al.
Publicado: (2023)

Anthrax outbreaks: an upcoming concern – commentary
por: Zaman, Kamran, et al.
Publicado: (2023)

Possible threat of the Omicron subvariant BF.7 to FIH Hockey World Cup 2023 in particular and the South-East Asia Region in general
por: Mohapatra, Ranjan K., et al.
Publicado: (2023)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Upsurge of Sports Injuries and Their Treatment
por: Vaishya, Raju, et al.
Publicado: (2017)

Infectious diseases upsurge in Mongolia
por: Devi, Sharmila
Publicado: (2020)

Upsurge in the construction of chiral nanomaterials
por: Tang, Zhiyong, et al.
Publicado: (2022)

Comment on: Women in ophthalmology- An upsurge!
por: Kurian, Merina
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Moving targets: COVID-19 vaccine efficacy against Omicron subvariants
por: da Silva, Maria Karolaynne, et al.
Publicado: (2022)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Response to the comment on Women in ophthalmology - An upsurge!
por: Bansal, Rolika, et al.
Publicado: (2022)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Old question with new omicron subvariant: Shall we put the masks back on?
por: Ma, Shaodi, et al.
Publicado: (2022)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l4m6frf2hgrb26qfo9o9g6ncio